Search

Your search keyword '"Sexson Tejtel, S. Kristen"' showing total 43 results
Start Over Author "Sexson Tejtel, S. Kristen"
43 results on '"Sexson Tejtel, S. Kristen"'

2. Loss of Consciousness in the Young Child

Author

Villafane, Juan, Miller, Jacob R., Glickstein, Julie, Johnson, Jonathan N., Wagner, Jonathan, Snyder, Chris S., Filina, Tatiana, Pomeroy, Scott L., Sexson-Tejtel, S. Kristen, Haxel, Caitlin, Gottlieb, Jason, Eghtesady, Pirooz, and Chowdhury, Devyani

Published
2021
Full Text
View/download PDF

3. Atrial septal defect closure is associated with improved clinical status in patients ≤ 10 kg with bronchopulmonary dysplasia

Author

Webb, Melissa K., primary, Cuevas Guaman, Milenka, additional, Sexson Tejtel, S. Kristen, additional, Cambronero, Neil, additional, Coleman, Ryan D., additional, Chartan, Corey A., additional, Yilmaz Furtun, Betul, additional, Morris, Shaine A., additional, Varghese, Nidhy P., additional, and Villafranco, Natalie M., additional

Published
2023
Full Text
View/download PDF

21. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination

Author

Truong, Dongngan T., primary, Dionne, Audrey, additional, Muniz, Juan Carlos, additional, McHugh, Kimberly E., additional, Portman, Michael A., additional, Lambert, Linda M., additional, Thacker, Deepika, additional, Elias, Matthew D., additional, Li, Jennifer S., additional, Toro-Salazar, Olga H., additional, Anderson, Brett R., additional, Atz, Andrew M., additional, Bohun, C. Monique, additional, Campbell, M. Jay, additional, Chrisant, Maryanne, additional, D’Addese, Laura, additional, Dummer, Kirsten B., additional, Forsha, Daniel, additional, Frank, Lowell H., additional, Frosch, Olivia H., additional, Gelehrter, Sarah K., additional, Giglia, Therese M., additional, Hebson, Camden, additional, Jain, Supriya S., additional, Johnston, Pace, additional, Krishnan, Anita, additional, Lombardi, Kristin C., additional, McCrindle, Brian W., additional, Mitchell, Elizabeth C., additional, Miyata, Koichi, additional, Mizzi, Trent, additional, Parker, Robert M., additional, Patel, Jyoti K., additional, Ronai, Christina, additional, Sabati, Arash A., additional, Schauer, Jenna, additional, Sexson Tejtel, S. Kristen, additional, Shea, J. Ryan, additional, Shekerdemian, Lara S., additional, Srivastava, Shubhika, additional, Votava-Smith, Jodie K., additional, White, Sarah, additional, and Newburger, Jane W., additional

Published
2022
Full Text
View/download PDF

22. Myocarditis and pericarditis: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data

Author

Sexson Tejtel, S. Kristen, Munoz, Flor M., Al-Ammouric, Iyad, Savorgnand, Fabio, Guggillae, Rama K., Khuri-Bulosf, Najwa, Phillips, Lee, and Engler, Renata J.M.

Subjects
Myocarditis, Case definition, Adverse events, CEPI, Pericarditis, Immunization, Guidelines, Myopericarditis, Brighton Collaboration
Abstract

Myocarditis and/or pericarditis (also known as myopericarditis) are inflammatory diseases involving the myocardium (with non-ischemic myocyte necrosis) and/or the pericardial sac. Myocarditis/pericarditis (MPC) may present with variable clinical signs, symptoms, etiologies and outcomes, including acute heart failure, sudden death, and chronic dilated cardiomyopathy. Possible undiagnosed and/or subclinical acute myocarditis, with undefined potential for delayed manifestations, presents further challenges for diagnosing an acute disease and may go undetected in the setting of infection as well as adverse drug/vaccine reactions. The most common causes of MPC are viral, with non-infectious, drug/vaccine associated hypersensitivity and/ or autoimmune causes being less well defined and with potentially different inflammatory mechanisms and treatment responses. Potential cardiac adverse events following immunization (AEFIs) encompass a larger scope of diagnoses such as triggering or exacerbating ischemic cardiac events, cardiomyopathy with potential heart failure, arrhythmias and sudden death. The current published experience does not support a potential causal association with vaccines based on epidemiologic evidence of relative risk increases compared with background unvaccinated incidence. The only evidence supporting a possible causal association of MPC with a vaccine comes from case reports. Hypersensitivity MPC as a drug/vaccine induced cardiac adverse event has long been a concern for postlicensure safety surveillance, as well as safety data submission for licensure. Other cardiac adverse events, such as dilated cardiomyopathy, were also defined in the CDC definitions for adverse events after smallpox vaccination in 2006. In addition, several groups have attempted to develop and improve the definition and adjudication of post-vaccination cardiovascular events. We developed the current case definitions for myocarditis and pericarditis as an AEFI building on experience and lessons learnt, as well as a comprehensive literature review. Considerations of other etiologies and causal relationships are outside the scope of this document. &nbsp

Published
2021

24. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial

Author

Burns, Jane C, primary, Roberts, Samantha C, additional, Tremoulet, Adriana H, additional, He, Feng, additional, Printz, Beth F, additional, Ashouri, Negar, additional, Jain, Supriya S, additional, Michalik, David E, additional, Sharma, Kavita, additional, Truong, Dongngan T, additional, Wood, James B, additional, Kim, Katherine K, additional, Jain, Sonia, additional, Anand, Vikram, additional, Anderson, Marsha, additional, Ang, Jocelyn, additional, Ansusinha, Emily, additional, Arditi, Moshe, additional, Bartlett, Allison, additional, Baker, Annette, additional, Chatterjee, Archana, additional, DeBiasi, Roberta, additional, De Ferranti, Sarah, additional, Dekker, Cornelia, additional, DeZure, Chandani, additional, Dominguez, Samuel, additional, Erdem, Guliz, additional, Halasa, Natasha, additional, Harahsheh, Ashraf S., additional, Hite, Michelle, additional, Jaggi, Preeti, additional, Jone, Pei-Ni, additional, Jones, Jessica, additional, Kaushik, Neeru, additional, Kumar, Madan, additional, Kurio, Gregory, additional, Lloyd, David, additional, Manaloor, John, additional, McNelis, Amy, additional, Nadipuram, Santhosh, additional, Newburger, Jane, additional, Newcomer, Charles, additional, Perkins, Tiffany, additional, Portman, Michael, additional, Romero, José R, additional, Rometo, Allison, additional, Ronis, Tova, additional, Rosenkranz, Margalit, additional, Rowley, Anne, additional, Samuy, Nichole, additional, Scalici, Paul, additional, Schuster, Jennifer, additional, Sexson Tejtel, S. Kristen, additional, Simonsen, Kari, additional, Szmuszkovicz, Jacqueline, additional, and Yeh, Sylvia, additional

Published
2021
Full Text
View/download PDF

33. Chronic Maternal Hyperoxygenation and Effect on Cerebral and Placental Vasoregulation and Neurodevelopment in Fetuses with Left Heart Hypoplasia

Author

Edwards, Lindsay A., primary, Lara, Diego A., additional, Sanz Cortes, Magdalena, additional, Hunter, Jill V., additional, Andreas, Shelley, additional, Nguyen, Magnolia J., additional, Schoppe, Lacey J., additional, Zhang, Jianhong, additional, Smith, Eboni M., additional, Maskatia, Shiraz A., additional, Sexson-Tejtel, S. Kristen, additional, Lopez, Keila N., additional, Lawrence, Emily J., additional, Wang, Yunfei, additional, Challman, Melissa, additional, Ayres, Nancy A., additional, Altman, Carolyn A., additional, Aagaard, Kjersti, additional, Becker, Judith A., additional, and Morris, Shaine A., additional

Published
2018
Full Text
View/download PDF

35. Chronic Maternal Hyperoxygenation and Effect on Cerebral and Placental Vasoregulation and Neurodevelopment in Fetuses with Left Heart Hypoplasia.

Author

Edwards, Lindsay A., Lara, Diego A., Sanz Cortes, Magdalena, Hunter, Jill V., Andreas, Shelley, Nguyen, Magnolia J., Schoppe, Lacey J., Zhang, Jianhong, Smith, Eboni M., Maskatia, Shiraz A., Sexson-Tejtel, S. Kristen, Lopez, Keila N., Lawrence, Emily J., Wang, Yunfei, Challman, Melissa, Ayres, Nancy A., Altman, Carolyn A., Aagaard, Kjersti, Becker, Judith A., and Morris, Shaine A.

Subjects
HYPOPLASTIC left heart syndrome, VASCULAR resistance, POSTNATAL care, REGRESSION analysis, INFANTS
Abstract

Introduction: In a pilot study of chronic maternal hyperoxygenation (CMH) in left heart hypoplasia (LHH), we sought to determine effect estimates of CMH on head size, vascular resistance indices, and neurodevelopment compared to controls.Material and Methods: Nine gravidae meeting the inclusion criteria (fetal LHH, ≥25.9 weeks' gestation, and ≥10% increase in percent aortic flow after acute hyperoxygenation) were prospectively enrolled. Controls were 9 contemporary gravidae with fetal LHH without CMH. Brain growth and Doppler-derived estimates of fetal cerebrovascular and placental resistance were blindly evaluated and compared using longitudinal regression. Postnatal anthropomorphic and neurodevelopmental assessments were compared.Results: There was no difference in baseline fetal measures between groups. There was significantly slower biparietal diameter (BPD) growth in the CMH group (z-score change -0.03 ± 0.02 vs. +0.09 ± 0.05 units/week, p = 0.02). At 6 months postnatal age, the mean head circumference z-score in the CMH group was smaller than that of controls (-0.20 ± 0.58 vs. +0.85 ± 1.11, p = 0.048). There were no differences in neurodevelopmental testing at 6 and 12 months.Discussion: In this pilot study, relatively diminished fetal BPD growth and smaller infant head circumference z-scores at 6 months were noted with in utero CMH exposure. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

41. Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in Children.

Author

Elias, Matthew D., Truong, Dongngan T., Oster, Matthew E., Trachtenberg, Felicia L., Mu, Xiangyu, Jone, Pei-Ni, Mitchell, Elizabeth C., Dummer, Kirsten B., Sexson Tejtel, S. Kristen, Osakwe, Onyekachukwu, Thacker, Deepika, Su, Jennifer A., Bradford, Tamara T., Burns, Kristin M., Campbell, M. Jay, Connors, Thomas J., D'Addese, Laura, Forsha, Daniel, Frosch, Olivia H., and Giglia, Therese M.

Published
2023
Full Text
View/download PDF

43. Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design.

Author

Gross RS, Thaweethai T, Rosenzweig EB, Chan J, Chibnik LB, Cicek MS, Elliott AJ, Flaherman VJ, Foulkes AS, Gage Witvliet M, Gallagher R, Gennaro ML, Jernigan TL, Karlson EW, Katz SD, Kinser PA, Kleinman LC, Lamendola-Essel MF, Milner JD, Mohandas S, Mudumbi PC, Newburger JW, Rhee KE, Salisbury AL, Snowden JN, Stein CR, Stockwell MS, Tantisira KG, Thomason ME, Truong DT, Warburton D, Wood JC, Ahmed S, Akerlundh A, Alshawabkeh AN, Anderson BR, Aschner JL, Atz AM, Aupperle RL, Baker FC, Balaraman V, Banerjee D, Barch DM, Baskin-Sommers A, Bhuiyan S, Bind MC, Bogie AL, Bradford T, Buchbinder NC, Bueler E, Bükülmez H, Casey BJ, Chang L, Chrisant M, Clark DB, Clifton RG, Clouser KN, Cottrell L, Cowan K, D'Sa V, Dapretto M, Dasgupta S, Dehority W, Dionne A, Dummer KB, Elias MD, Esquenazi-Karonika S, Evans DN, Faustino EVS, Fiks AG, Forsha D, Foxe JJ, Friedman NP, Fry G, Gaur S, Gee DG, Gray KM, Handler S, Harahsheh AS, Hasbani K, Heath AC, Hebson C, Heitzeg MM, Hester CM, Hill S, Hobart-Porter L, Hong TKF, Horowitz CR, Hsia DS, Huentelman M, Hummel KD, Irby K, Jacobus J, Jacoby VL, Jone PN, Kaelber DC, Kasmarcak TJ, Kluko MJ, Kosut JS, Laird AR, Landeo-Gutierrez J, Lang SM, Larson CL, Lim PPC, Lisdahl KM, McCrindle BW, McCulloh RJ, McHugh K, Mendelsohn AL, Metz TD, Miller J, Mitchell EC, Morgan LM, Müller-Oehring EM, Nahin ER, Neale MC, Ness-Cochinwala M, Nolan SM, Oliveira CR, Osakwe O, Oster ME, Payne RM, Portman MA, Raissy H, Randall IG, Rao S, Reeder HT, Rosas JM, Russell MW, Sabati AA, Sanil Y, Sato AI, Schechter MS, Selvarangan R, Sexson Tejtel SK, Shakti D, Sharma K, Squeglia LM, Srivastava S, Stevenson MD, Szmuszkovicz J, Talavera-Barber MM, Teufel RJ 2nd, Thacker D, Trachtenberg F, Udosen MM, Warner MR, Watson SE, Werzberger A, Weyer JC, Wood MJ, Yin HS, Zempsky WT, Zimmerman E, and Dreyer BP

Subjects
Humans, Adolescent, Child, Child, Preschool, Female, Young Adult, Adult, Male, Infant, SARS-CoV-2 isolation & purification, Infant, Newborn, Prospective Studies, Research Design, Cohort Studies, Post-Acute COVID-19 Syndrome, COVID-19 epidemiology, COVID-19 virology
Abstract

Importance: The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or "Long COVID") in children and young adults remain unknown. Studies must address the urgent need to define PASC, its mechanisms, and potential treatment targets in children and young adults., Observations: We describe the protocol for the Pediatric Observational Cohort Study of the NIH's REsearching COVID to Enhance Recovery (RECOVER) Initiative. RECOVER-Pediatrics is an observational meta-cohort study of caregiver-child pairs (birth through 17 years) and young adults (18 through 25 years), recruited from more than 100 sites across the US. This report focuses on two of four cohorts that comprise RECOVER-Pediatrics: 1) a de novo RECOVER prospective cohort of children and young adults with and without previous or current infection; and 2) an extant cohort derived from the Adolescent Brain Cognitive Development (ABCD) study (n = 10,000). The de novo cohort incorporates three tiers of data collection: 1) remote baseline assessments (Tier 1, n = 6000); 2) longitudinal follow-up for up to 4 years (Tier 2, n = 6000); and 3) a subset of participants, primarily the most severely affected by PASC, who will undergo deep phenotyping to explore PASC pathophysiology (Tier 3, n = 600). Youth enrolled in the ABCD study participate in Tier 1. The pediatric protocol was developed as a collaborative partnership of investigators, patients, researchers, clinicians, community partners, and federal partners, intentionally promoting inclusivity and diversity. The protocol is adaptive to facilitate responses to emerging science., Conclusions and Relevance: RECOVER-Pediatrics seeks to characterize the clinical course, underlying mechanisms, and long-term effects of PASC from birth through 25 years old. RECOVER-Pediatrics is designed to elucidate the epidemiology, four-year clinical course, and sociodemographic correlates of pediatric PASC. The data and biosamples will allow examination of mechanistic hypotheses and biomarkers, thus providing insights into potential therapeutic interventions., Clinical Trials.gov Identifier: Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT05172011., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Brett Anderson reported receiving direct support for work not related to RECOVER work/publications from Genentech and the National Institute of Allergy and Immunology. Walter Dehority reported receiving grant support from Merck and participating in research for the Moderna COVID-19 pediatric vaccine trial and the Pfizer Paxlovid trial. Alex Fiks reported receiving support from NJM insurance and personal consulting fees not related to this paper from Rutgers University and the American Academy of Pediatrics. Ashraf Harahsheh reported serving as a scientific advisory board member unrelated to this paper for OP2 DRUGS. Lawrence Kleinman reported serving as an unpaid member of the Board of Directors for the DARTNet Institute, as a principle investigator at Quality Matters, Inc., and as the Vice Chair for the Borough of Metuchen Board of Health. Dr. Kleinman also reported grant support for work not related to RECOVER work/publications from NIH, HRSA, and the Robert Wood Johnson Foundation. Dr. Kleinman also reported minority individual stock ownership in Apple Computer, Sanofi SA, Experion, GlaxoSmithKline, Magyar Bank, Regeneron Pharmaceuticals, JP Morgan Chase, and Amgen Inc. Torri Metz reported participating as a Principle Investigator in the medical advisory board for the planning of a Pfizer clinical trial of SARS-CoV-2 vaccination in pregnancy. She is also a principle investigator for a Pfizer study evaluating the pharmacokinetics of Paxlovid in pregnant people with COVID-19. Joshua Milner reported serving as a member of the Scientific Advisory Board for Blueprint Medicines, in a capacity unrelated to RECOVER work/publications. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2024 Gross et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results